scispace - formally typeset
Open AccessJournal ArticleDOI

Overview of the European and North American studies on HPV testing in primary cervical cancer screening.

TLDR
The results support the use of HPV testing as the sole primary screening test, with cytology reserved for women who test HPV positive, with large demonstration projects needed to fully evaluate this strategy.
Abstract
Several studies suggest that HPV testing is more sensitive than cytology in primary cervical screening. These studies had different designs and were reported in different ways. Individual patient data were collected for all European and North American studies in which cytology was routinely performed and HPV testing was included as an additional parallel test. More than 60,000 women were included. The sensitivity and specificity of HPV testing were compared with routine cytology, both overall and for ages <35, 35–49 and 50+. The age-specific prevalence of high risk HPV (hr-HPV) was also analysed. HPV testing was substantially more sensitive in detecting CIN2+ than cytology (96.1% vs. 53.0%) but less specific (90.7% vs. 96.3%). The sensitivity of HPV testing was similar in all studies carried out in different areas of Europe and North America, whereas the sensitivity of cytology was highly variable. HPV sensitivity was uniformly high at all ages, whereas the sensitivity of cytology was substantially better in women over the age of 50 than in younger women (79.3% vs. 59.6%). The specificity of both tests increased with age. Positivity rates for HPV testing in women without high-grade CIN were region dependent. These results support the use of HPV testing as the sole primary screening test, with cytology reserved for women who test HPV positive. Large demonstration projects are needed to fully evaluate this strategy. © 2006 Wiley-Liss, Inc.

read more

Citations
More filters
Journal ArticleDOI

The value of adding a single co-test in HPV primary screening.

TL;DR: In this paper, the authors examined how many cases of HPV negative cervical dysplasia that were found in this age-group, to be able to estimate the value of adding a co-test in an HPV screening program.
Journal ArticleDOI

Implementation of an HPV-Vaccination Program

TL;DR: For settings that have a high burden of cervical cancer but that have not implemented screening, additional trial and registry data that not only confirm the initial results showing high efficacy but also show significant reductions in pre-cancer, and ultimately cancer, will provide reassurance that a decision to implement an HPV vaccination program is sound.
Journal ArticleDOI

Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research

TL;DR: Addressing genetics, risk modeling, molecular targets for chemoprevention, clinical prevention trials, behavioral prevention research, public policy, and more, the Fifth Annual International Conference on Frontiers in Cancer Prevention Research, held in Boston, Massachusetts, in November 2006, added an outstanding new chapter to the landmark AACR Frontiers program.
Journal ArticleDOI

Colorectal cancer prevention through screening: population acceptance of flexible sigmoidoscopy.

TL;DR: Overall, the ACOG guidelines are a significant step in the right direction, but it is important to point out that these are not fully ‘evidence-based’ guidelines.
Journal Article

Cytology and DNA HPV-Testing in the Era of HPV-Vaccine

TL;DR: In this paper, a wide-spread public vaccination against human papillomavirus (HPV) persistent infection is the main factor leading to cervical cancer carcinogenesis, and screening for precancerous lesions cannot be discontinued because vaccination will not protect against HPV types not included in the first and second generation vaccines.
References
More filters
Journal ArticleDOI

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

TL;DR: The presence of HPV in virtually all cervical cancers implies the highest worldwide attributable fraction so far reported for a specific cause of any major human cancer, and the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening.
Journal ArticleDOI

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study

TL;DR: The findings suggest that attempts to exploit the association between cervical neoplasia and HPV infection to improve effectiveness of cervical screening programmes might be undermined by the limited inferences that can be drawn from the characterisation of a woman's HPV status at a single point in time, and the short lead time gained by its detection.
Journal ArticleDOI

Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study

TL;DR: Persistent infection with high-risk human papillomavirus is necessary for development and maintenance of cervical intraepithelial neoplasia CIN 3, and all women with severe dyskaryosis should be referred to gynaecologists, whereas women with mild to moderate dysKaryosis ought to be referred only after a second positive test for high- risk human papillsomav virus at 6 months.
Journal ArticleDOI

Trends in mortality from cervical cancer in the nordic countries: association with organised screening programmes

TL;DR: Investigation of time trends in mortality from cervical cancer in Denmark, Finland, Iceland, Norway, and Sweden since the early 1950s supports the conclusion that organised screening programmes have had a major impact on the reduction in mortality in the Nordic countries.
Journal ArticleDOI

Management of women who test positive for high-risk types of human papillomavirus: The HART study

TL;DR: Comparison of the detection rate and positive predictive values of HPV assay with cytology and the best management strategy for HPV-positive women found HPV testing was more sensitive than borderline or worse cytology but less specific for detecting CIN2+.
Related Papers (5)